Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Brian M. Wolpin, Andrew J. Aguirre et al.|Cancer Discovery|2024Cited by 234
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical ModelsLars D. Engstrom, James G. Christensen, Ruth Aranda et al.|Clinical Cancer Research|2017Cited by 147
Supplemental Table 2 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Brian M. Wolpin, Megan T. Hoffman et al.|Unknown|2024Cited by 0
Supplemental Table 1 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Brian M. Wolpin, Megan T. Hoffman et al.|Unknown|2024Cited by 0
Supplemental Table 7 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Brian M. Wolpin, Megan T. Hoffman et al.|Unknown|2024Cited by 0